Elevance Health Q4 EPS Forecast Boosted by Leerink Partnrs

Elevance Health, Inc. (NYSE:ELV - Free Report) - Equities research analysts at Leerink Partnrs upped their Q4 2025 earnings per share estimates for Elevance Health in a report issued on Thursday, July 17th. Leerink Partnrs analyst W. Mayo now anticipates that the company will post earnings of $4.24 per share for the quarter, up from their prior estimate of $4.03. Leerink Partnrs has a "Hold" rating on the stock. The consensus estimate for Elevance Health's current full-year earnings is $33.96 per share.

Elevance Health (NYSE:ELV - Get Free Report) last released its quarterly earnings results on Thursday, July 17th. The company reported $8.84 EPS for the quarter, missing the consensus estimate of $9.30 by ($0.46). The business had revenue of $49.42 billion during the quarter, compared to analysts' expectations of $48.26 billion. Elevance Health had a net margin of 2.83% and a return on equity of 17.59%. The firm's revenue for the quarter was up 14.3% compared to the same quarter last year. During the same quarter last year, the company earned $10.12 EPS.

A number of other research firms have also recently weighed in on ELV. Argus set a $465.00 price objective on Elevance Health in a research report on Friday, April 25th. Wall Street Zen downgraded Elevance Health from a "buy" rating to a "hold" rating in a report on Friday. Wells Fargo & Company lowered their price objective on shares of Elevance Health from $478.00 to $400.00 and set an "overweight" rating on the stock in a research report on Tuesday, July 15th. Mizuho upped their price objective on shares of Elevance Health from $455.00 to $505.00 and gave the stock an "outperform" rating in a research report on Wednesday, April 9th. Finally, Morgan Stanley reduced their target price on shares of Elevance Health from $428.00 to $316.00 and set an "overweight" rating for the company in a research note on Friday. Six research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $435.93.

Elevance Health Stock Performance

NYSE ELV opened at $276.87 on Monday. The firm has a market cap of $62.35 billion, a P/E ratio of 11.78, a P/E/G ratio of 0.81 and a beta of 0.60. Elevance Health has a 52-week low of $276.41 and a 52-week high of $567.26. The business's 50-day moving average price is $371.52 and its 200 day moving average price is $396.02. The company has a quick ratio of 1.44, a current ratio of 1.44 and a debt-to-equity ratio of 0.64.

Hedge Funds Weigh In On Elevance Health

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Accredited Wealth Management LLC acquired a new position in shares of Elevance Health during the 4th quarter worth approximately $25,000. Private Wealth Management Group LLC raised its holdings in shares of Elevance Health by 152.0% in the first quarter. Private Wealth Management Group LLC now owns 63 shares of the company's stock worth $27,000 after acquiring an additional 38 shares during the last quarter. WealthTrak Capital Management LLC acquired a new position in shares of Elevance Health in the fourth quarter worth $29,000. WPG Advisers LLC purchased a new stake in shares of Elevance Health in the first quarter valued at $29,000. Finally, Lee Danner & Bass Inc. acquired a new stake in shares of Elevance Health during the fourth quarter valued at $30,000. Institutional investors and hedge funds own 89.24% of the company's stock.

Insider Activity at Elevance Health

In other news, CEO Gail Boudreaux bought 8,500 shares of the firm's stock in a transaction on Friday, July 18th. The shares were bought at an average cost of $286.94 per share, for a total transaction of $2,438,990.00. Following the completion of the transaction, the chief executive officer owned 151,020 shares in the company, valued at $43,333,678.80. This trade represents a 5.96% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Mark Kaye sold 4,588 shares of Elevance Health stock in a transaction on Thursday, April 24th. The stock was sold at an average price of $424.82, for a total value of $1,949,074.16. Following the transaction, the chief financial officer directly owned 18,977 shares of the company's stock, valued at $8,061,809.14. This trade represents a 19.47% decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.29% of the company's stock.

Elevance Health Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 25th. Investors of record on Wednesday, September 10th will be paid a $1.71 dividend. This represents a $6.84 annualized dividend and a yield of 2.47%. The ex-dividend date of this dividend is Wednesday, September 10th. Elevance Health's payout ratio is currently 29.11%.

Elevance Health Company Profile

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.